Board of Directors Establishes Interim Office of the CEO and Initiates Search for a Successor to Lead Company Through Next Phase of Development and Commercialization SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2024 /PRNewswire/ -- Freenome today announced that Mike Nolan has resigned from his position as chief executive officer (CEO) for personal reasons.
The Board of Directors has established an interim Office of the CEO, led by Freenome's co-founder Riley Ennis , with assistance from Douglas VanOort , a Freenome Board member and former chairman of the board and CEO at NeoGenomics, to provide leadership continuity and operational management during the transition. Mr. Nolan will serve as a consultant to the company and its board.
The board will be selecting a successor to guide the organization toward commercialization and increasing its public presence as Freenome focuses on bringing blood-based screening to patients. "It has been an honor to work alongside my talented colleagues at Freenome over the past six years," Mr. Nolan said, "I continue to be confident about Freenome's strategic direction and its ability to achieve its goals in the fight against cancer.
" Randy Scott , Ph.D., CEO at Genomic Life and a Freenome board member since 2017, said, "We are grateful to Mike for his contributions to Freenome throughout his tenure.
As CEO, Mike played an important role in Freenome's recent financing and advancing the company's programs. We are in a strong position and wish him all t.
